TVARDI THERAPEUTICS, INC. financials

TVRD CIK 0001346830

Source: EDGAR filings · Built 2026-06-02T04:14:15Z

Custom taxonomy namespace: ffd

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Free Cash Flow -19.35M -94.45M -78.77M -60.13M -5.84M
EBITDA -26.65M -28.01M -121.24M -87.29M -88.83M 5.59M
Working Capital 20.50M 21.32M 90.57M 145.45M 155.67M 176.58M
Net Debt -20.53M -1.35M -45.69M -61.82M -9.78M -26.41M
Gross Margin 100.00%
Operating Margin -393.82% -579.43% -209.08% -386.85% 3.99%
Net Margin -411.90% -565.21% -204.16% -384.06% 6.23%
Return on Equity (ROE) -86.96% 32.26% 190.97% -53.83% -38.87% 3.38%
Return on Assets (ROA) -56.79% -83.52% -94.17% -46.90% -35.80% 3.10%
Current Ratio 2.86× 3.06× 4.54× 7.20× 9.84× 10.55×
Debt-to-Equity 0.01× -0.33× -0.10× 0.01× 0.02× 0.02×
Effective Tax Rate 0.00% 0.00% 0.00% 0.00% -8.95%
Cash Conversion Ratio 1.29× 0.62× 0.78× 0.92× 0.68× -0.65×
Accruals Ratio 0.16× -0.32× -0.21× -0.04× -0.11× 0.05×
SBC % of Revenue 4.47% 65.48% 42.36% 90.26% 10.98%
CapEx Coverage -17.50× -38.77× -1830.93× -1540.69× -15.72×
Free Cash Flow Per Share $-7.52 $-20.93 $-17.62 $-1.19 $-0.12

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/B 1.93×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenue from Contract with Customer, Excluding Assessed Tax 7.14M 20.97M 41.87M 23.03M 135.08M
Cost of Goods and Services Sold 0
Research and Development Expense 18.01M 23.65M 108.51M 91.88M 82.70M 107.85M
Operating Expenses 26.75M 28.11M 142.46M 129.40M 112.11M 129.70M
Operating Income (Loss) -26.75M -28.11M -121.50M -87.53M -89.08M 5.38M
Income Tax Expense (Benefit) 0 0 0 0 0 -691.00K
Net Income (Loss) Attributable to Parent -18.21M -29.40M -118.51M -85.47M -88.44M 8.41M
Earnings Per Share, Basic $-2.46 $-11.42 $-26.26 $-19.12 $-1.74 $0.18
Weighted Average Number of Shares Outstanding, Basic 7.42M 2.57M 4.51M 4.47M 50.72M 47.41M
Earnings Per Share, Diluted $-3.26 $-11.42 $-26.26 $-19.12 $-1.74 $0.18
Weighted Average Number of Shares Outstanding, Diluted 7.78M 2.57M 4.51M 4.47M 50.72M 47.92M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 20.73M 31.61M 51.77M 63.74M 13.45M 31.68M
Assets, Current 31.54M 31.69M 116.16M 168.91M 173.29M 195.06M
Assets 32.07M 35.20M 125.84M 182.24M 247.06M 271.16M
Liabilities, Current 11.04M 10.37M 25.59M 23.46M 17.62M 18.48M
Liabilities 11.13M 40.83M 68.76M 23.46M
Stockholders' Equity Attributable to Parent 20.95M -91.13M -62.06M 158.78M 227.52M 249.00M
Common Stock, Shares, Outstanding 9.38M 2.57M 4.54M 53.80M 53.48M 49.87M

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities -23.50M -18.30M -92.08M -78.73M -60.09M -5.49M
Payments to Acquire Property, Plant, and Equipment 1.05M 2.38M 43.00K 39.00K 349.00K
Net Cash Provided by (Used in) Investing Activities -10.08M 48.74M 43.46M 128.71M -4.75M -20.27M
Net Cash Provided by (Used in) Financing Activities 22.70M 27.00M 38.15M 311.00K 46.61M 39.14M

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (TVRD CIK 0001346830), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

NOC

NORTHROP GRUMMAN CORP /DE/

WBS

WEBSTER FINANCIAL CORPORATION

EDIT

Editas Medicine, Inc.